Advertisement
Advertisement
U.S. Markets open in 8 hrs 58 mins
Advertisement
Advertisement
Advertisement
Advertisement

ZIVO Bioscience, Inc. (ZIVO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.3400-0.1200 (-3.47%)
At close: 03:57PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4600
Open3.4900
Bid0.0000 x 800
Ask0.0000 x 1400
Day's Range3.1700 - 3.4900
52 Week Range2.1600 - 4.6000
Volume9,442
Avg. Volume8,783
Market Cap31.462M
Beta (5Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business

    BLOOMFIELD HILLS, Mich., October 24, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company’s corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generati

  • Business Wire

    ZIVO Bioscience CEO Issues Letter to Shareholders

    BLOOMFIELD HILLS, Mich., September 23, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.

  • Business Wire

    ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment

    BLOOMFIELD HILLS, Mich., August 10, 2022--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces receipt of a letter from the U.S. Department of Agriculture’s (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company’s novel immune-modulating biologic for treating cocc

Advertisement
Advertisement